TABLE 3.
Summary of results from all subgroup analyses
| ‐ | Subgrouped by | The number of studies | Effect size | 95% CI | I 2 (%) | p for between subgroup heterogeneity |
|---|---|---|---|---|---|---|
| HDL | Type of participants | – | – | – | – | .81 |
| dyslipidemia | 3 | 1.82 | −2.37, 6.00 | 0 | – | |
| without dyslipidemia | 7 | 2.35 | 0.84, 3.87 | 16 | – | |
| period of treatment | – | – | – | – | .30 | |
| >10 weeks | 6 | 2.81 | 1.08, 4.54 | 17 | – | |
| ≤10 weeks | 4 | 1.19 | −1.33, 3.71 | 0 | – | |
| LDL | Type of participants | – | – | – | – | .21 |
| dyslipidemia | 3 | −12.70 | −23.12, −2.27 | 0 | – | |
| without dyslipidemia | 7 | −5.41 | −10.10, −0.72 | 40 | – | |
| period of treatment | – | – | – | – | .79 | |
| >10 weeks | 6 | −6.20 | −11.55, −0.86 | 56 | – | |
| ≤10 weeks | 4 | −7.40 | −14.54, −0.27 | 0 | – | |
| TG | Type of participants | – | – | – | – | .36 |
| dyslipidemia | 3 | −14.40 | −33.52, 4.72 | 41 | – | |
| without dyslipidemia | 7 | −4.27 | −14.59, 6.06 | 50 | – | |
| period of treatment | – | – | – | – | .22 | |
| >10 weeks | 6 | −10.71 | −21.98, 0.56 | 8 | – | |
| ≤10 weeks | 4 | −1.15 | −14.20, 16.51 | 68 | – | |
| TC | Type of participants | – | – | – | – | .01 |
| dyslipidemia | 3 | −17.23 | −27.99, −6.47 | 8 | ||
| without dyslipidemia | 6 | −1.61 | −7.69, 4.47 | 45 | – | |
| period of treatment | – | – | – | – | .31 | |
| >10 weeks | 6 | −4.20 | −9.97, 1.56 | 62 | – | |
| ≤10 weeks | 3 | −11.70 | −25.03, 1.63 | 0 | – |
Abbreviations: HDL, high‐density lipoprotein cholesterol; LDL, low‐density lipoprotein cholesterol; TC, total cholesterol; TG, Triglyceride.